



Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19

Philippine Eloy, Coralie Tardivon, Guillaume Martin-Blondel, Margaux Isnard, Paul Le Turnier, Marion Le Marechal, André Cabié, Odile Launay, Pierre Tattevin, Eric Senneville, et al.

► To cite this version:

Philippine Eloy, Coralie Tardivon, Guillaume Martin-Blondel, Margaux Isnard, Paul Le Turnier, et al.. Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19: a prospective cohort study. *International Journal of Infectious Diseases*, 2021, 112, pp.247-253. 10.1016/j.ijid.2021.09.011 . hal-03369814

HAL Id: hal-03369814

<https://hal.science/hal-03369814>

Submitted on 5 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19: a prospective cohort study

Running title: Severity of persistent symptoms 6 months after hospitalization for COVID-19

Philippine ELOY^{1,2}, Coralie TARDIVON^{1,2}, Guillaume MARTIN-BLONDEL³, Margaux ISNARD⁴, Paul LE TURNIER⁵, Marion LE MARECHAL⁶, André CABIÉ⁷, Odile LAUNAY⁸, Pierre TATTEVIN⁹, Eric SENNEVILLE¹⁰, Séverine ANSART¹¹, François GOEHRINGER¹², Catherine CHIROUZE¹³, Laurane BOUSSON², Cédric LAOUÉANAN^{1,2,14}, Manuel ETIENNE¹⁵, Duc NGUYEN¹⁶, Jade GHOSN^{14,17}, Xavier DUVAL^{14,18} and the French COVID cohort study and investigators groups*

¹AP-HP, Hôpital Bichat, Département Epidémiologie Biostatistiques et Recherche Clinique, F-75018 Paris, France

²INSERM, Centre d'Investigations cliniques-Epidémiologie Clinique 1425, Hôpital Bichat, F-75018 Paris, France

³Service des Maladies Infectieuses et Tropicales, CHU de Toulouse

⁴Service de Maladies Infectieuses et Médecine Interne, CH Métropole Savoie

⁵Department of Infectious Diseases, Hotel-Dieu Hospital - INSERM CIC 1413, Nantes University Hospital, Nantes, France

⁶CHU Grenoble Rhône Alpes, Service de Maladies Infectieuses et Médecine Tropicale, F-38000 Grenoble, France

22 ⁷Inserm CIC 1424, Université des Antilles EA 7524, Service de maladies infectieuses et
23 tropicales, CHU de Martinique, F-97200 Fort-de-France, France

24 ⁸Inserm CIC 1417, Faculté de Médecine Paris Descartes, Univ Paris, AP-HP, Hôpital Cochin,
25 Paris, France

26 ⁹Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, University
27 Rennes-1, Rennes, France

28 ¹⁰Infectious Diseases Department, Gustave Dron Hospital, 59200 Tourcoing, France

29 ¹¹Tropical and Infection Diseases Unit, CHRU de Brest, F-29200 Brest, France

30 ¹²Service de Maladies Infectieuses et Tropicales, Centre Régional Universitaire de Nancy,
31 Hôpitaux de Brabois, Rue du Morvan, 54511 Vandoeuvre Lés Nancy, France

32 ¹³CHU Besançon, Service de Maladie Infectieuses et Tropicales, F-25000, Besançon, France

33 ¹⁴Université de Paris, INSERM, IAME UMR 1137, Paris, France

34 ¹⁵CHU Rouen, Service des Maladies Infectieuses et Tropicales, F-76000 Rouen, France

35 ¹⁶Department of Infectious and Tropical Diseases, CHU de Bordeaux, Bordeaux, France

36 ¹⁷AP-HP, Hôpital Bichat, Infectious and Tropical Diseases Department, Paris, France

37 ¹⁸AP-HP, Hôpital Bichat, Centre d'Investigation Clinique, Inserm CIC 1425, F-75018 Paris,
38 France

39 **Corresponding author:** Philippine ELOY

40 E-mail : philippine.eloy@aphp.fr

41 Phone number : +33 1 40 25 68 87

42 Postal address : AP-HP, Hôpital Bichat, Département Epidémiologie Biostatistiques et
43 Recherche Clinique, 46, rue Henri Huchard, 75018 Paris, France

44

45 *Membership of the French COVID cohort study and investigators groups is provided in the
46 Supplementary Material.

47 **Abstract**

48 **Objectives:** Few studies have reported clinical COVID-19 sequelae six months (M6) after
49 hospital discharge, but none has studied symptom severity.

50 **Methods:** Prevalence and severity of 7 symptoms were estimated until M6 using the self-
51 administered influenza severity scale in COVID-19 hospitalized patients enrolled in the French
52 COVID cohort. Factors associated with severity were assessed by logistic regression. Anxiety,
53 depression and health-related quality of life (HRQL) were also assessed.

54 **Results:** At M6, among the 324 patients (median age 61 years, 63% men, 19% admitted to
55 intensive care during the acute phase), 187/324 (58%) reported at least one symptom mostly
56 fatigue (47%) and myalgia (23%). Symptom severity was scored, at most, mild in 125 (67%),
57 moderate in 44 (23%) and severe in 18 (10%). Female gender was the sole factor associated
58 with moderate/severe symptom reporting (OR = 1.98, 95%CI=1.13-3.47). Among the 225
59 patients with psychological assessment, 24 (11%) had anxiety, 18 (8%) depressive symptoms,
60 and their physical HRQL was significantly poorer than the general population (p=0.0005).

61 **Conclusion:** Even if 58% of patients reported ≥ 1 symptom at M6, less than 7% rated any
62 symptom as severe. Assessing symptoms severity could be helpful to identify patients requiring
63 appropriate medical care. Women may require special attention.

64 **Keywords :** COVID-19 - Sequelae – Persistent symptoms – Risk factors

65 **Abstract word count:** 200 words / **Text word count:** 2678 words

Introduction

Since the first cases of SARS-CoV-2 infection in December 2019, clinical presentation of COVID-19 in its acute phase has been largely described (Docherty et al., 2020; Richardson et al., 2020). However, long-term clinical sequelae of COVID-19 remains unclear. A few studies reported persistent symptoms 2 to 4 months post discharge (Carfi et al., 2020; Garrigues et al., 2020; Xiong et al., 2021). More recently, Huang et al. described the 6-months consequences of COVID-19 and reported presence of fatigue or myalgia in 63% of patients in an inpatients single-center cohort in China (Huang et al., 2021).

Here in a multicenter prospective cohort in France, we assessed self-reported symptoms 6 months after hospital admission for COVID-19, using the influenza severity scale and described the evolution following diagnosis. We also assessed anxiety, depression and health-related quality of life (HRQL) to measure the impact of these symptoms on patients' global health.

Material and Methods

Study oversight

The French COVID cohort (NCT04262921) is a national prospective multi-center cohort study enrolling hospitalized patients with a RT-PCR virologically-confirmed COVID-19 in 80 hospitals in France since January 24, 2020 (Yazdanpanah and French COVID cohort investigators and study group, 2021). Briefly, patients were followed-up from hospital admission (D1) throughout hospitalization for COVID-19 and at discharge, 2 to 4 weeks after discharge, month 3 (M3) and 6 (M6). The assessment of symptoms, anxiety, depression and health-related quality of life using self-administered questionnaires were proposed to the patients at each visit. All adult patients who fulfilled the self-administered symptoms

questionnaire at months 3 (M3) and 6 (M6) by March 22nd, 2021 were included in the present analysis.

Procedures

The self-administered symptoms questionnaire recorded the presence and the severity of the following symptoms: fatigue, myalgia, headache, cough, nasal obstruction, sore throat and feverishness. All symptoms were rated by the patient using a four-point scale (0, none; 1, mild; 2, moderate; 3, severe) using a self-administered questionnaire previously used in influenza infection (Duval et al., 2010; Hayden et al., 1997). For each date of evaluation, a total score ranging from 0 to 21 was obtained by summing the points attributed for each symptom. Based on the definition of symptom alleviation used in influenza, reporting of at least one moderate or severe symptom was considered to reflect an abnormal state of health. Four additional COVID-19 symptoms (joint pain, dyspnea, anosmia and ageusia) which were not included in the influenza questionnaire were also collected by the practitioner (thereafter referred to as “practitioner reported symptoms”) during M3 and M6 visits.

Anxiety and depression symptoms were assessed using the Hospital Anxiety and Depression scale (HADS), subdivided in the HADS-Anxiety (HADS-A) and the HADS-Depression (HADS-D) scales. Both scales contain 7 questions scored by the patients on a 4-point Likert scale (0–3) with higher scores indicating more severe anxiety/depression. The items scores were summed up separately for HADS-A and HADS-D, leading to two scores ranging between 0 and 21. Scores greater than or equal to 11 points indicated abnormal levels (Zigmond and Snaith, 1983).

Health-related quality of life (HRQL) was assessed using the SF-12 Health Survey (Gandek et al., 1998) including a Physical Component Summary (PCS) HRQL score and a Mental Component Summary (MCS) HRQL score. These scores range from 0 to 100, with a high value

indicating good HRQL. A patient was defined as having an altered physical (or mental) HRQL if his PCS (or MCS) was lower than the 25th percentile of the score distribution in the general French population of the same age group and gender (Carrieri et al., 2003).

The self-administered questionnaires were collected using REDCap electronic data capture tools (Harris et al., 2009) with a secured personal access given to each patient after hospital discharge.

Statistical analyses

Categorical variables were summarized as counts (percentage) and frequency distributions were compared with the Chi-square, the Fisher exact or the McNemar for paired samples tests as appropriate. Continuous variables were expressed as median [interquartile range (IQR)] unless otherwise specified and compared with the Mann-Whitney U test. Prevalence of symptoms are given with their 95% confidence interval, estimated by using the exact Clopper-Pearson method.

To assess the representativeness of the population of patients who fulfilled the questionnaire, demographic characteristics, comorbidities and clinical data at hospital admission were compared between patients who fulfilled or not the 7-symptoms questionnaire at M3 and M6 using logistic multivariate regression models. The latter were adjusted on age, sex and ethnic group, in order to assess for confounding variables.

Associations between having at least one moderate or severe symptom at M6 and baseline characteristics were assessed through univariate logistic regressions. All Variables were putted in the multivariate models. Variable selection was then performed by starting with a model that included all covariates and then excluding those that did not improve the overall fit as measured by the likelihood ratio test (LRT). A P-value cut-off point of .05 was used as stopping rule for this backward manual selection. Two-way interactions between risk factors kept in the

137 multivariate analysis (including “ICU during the acute phase”) were tested. No imputation
138 strategy was applied for missing data. Any case that has a missing value was discarded from
139 the analysis.

140 All tests were 2-sided and p-values $<.05$ were considered significant. All statistical analyses
141 were performed using R version 4.0.2.

Ethics and regulatory issues

The study was conducted with the understanding and the consent of each participant or its surrogate. The French Ethics Committee (CPP-Ile-de-France VI, ID RCB: 2020-A00256-33) has approved the study protocol.

Results

Patient characteristics

Of 3,497 French COVID cohort adult participants enrolled between January 24th and September 22nd, 2020, in order to allow for a six-month follow-up, 392 died during initial hospitalization and 45 between hospital discharge and M6. Out of the 3,060 patients alive at M6, 324 patients fulfilled the 7-symptoms questionnaire at M3 and M6 and represented the study population (Figure S1). The median time interval between hospital admission and M6 assessment was 185 [182-191] days.

The main demographic comorbidities and characteristics at admission of these 324 patients are presented in Table 1. The median age was 61 years [52-69], and 205 (63%) were men. The most common comorbidities were hypertension (n=110, 35%), chronic pulmonary disease (n=56, 18%), chronic cardiac disease (n=57, 18%), obesity (n=53, 17%) and diabetes (n=48, 15%). Fifty-four patients (19%) were admitted to intensive care unit (ICU) at any time during hospitalization.

As compared to the 2,736 patients who did not complete the 7-symptoms questionnaire at M3 and M6, the 324 patients were younger, less likely to have diabetes, chronic kidney disease at admission, or to have been hospitalized in ICU (Table S1).

Symptoms at M6

At Month 6, 187 (58%) of the 324 patients who completed the self-administered questionnaire reported at least one persistent symptom: 80 (25%) reported one symptom, 48 (15%) two and 59 (18%) ≥ 3 symptoms. A total 7-symptoms score ≥ 3 was found in 73 (22.5%, 95% CI = [18.1% ; 27.5%]) patients. Among these 187 patients, median [IQR] total 7-symptoms score was 2 [1-3].

Among the 7 self-reported symptoms, the most frequent was fatigue (n=151, 47%) which was scored as mild in 103 (68%), moderate in 32 (21%) and severe in 16 (11%) (Figure 1). Myalgia was the second most frequent symptom (n=74, 23%) which was scored as mild in 46 (62%), moderate in 22 (30%) and severe in 6 (8%) patients. Either of the 2 symptoms was reported in 160 (49%) patients. Among the 187 patients with at least 1 symptom, the severity of the reported symptoms was scored at most mild in two thirds (n=125, 67%), moderate in 44 (23%) and severe in 18 (10%).

Reporting of a moderate or severe symptom at M6 was only associated with female gender (OR = 1.98, 95% CI = 1.13 - 3.47) in multivariate analysis after variable selection, while age (OR = 0.94, 95% CI = 0.52 - 1.65), hospitalization in ICU (OR = 0.67, 95% CI = 0.28 - 1.44), or having ≥ 2 comorbidities (OR=1.13, 95% CI = 0.62 – 2.03) were not (Table S2).

Among the 324 analyzed patients, 301 (93%) had practitioner examination available at M6: the practitioner reported joint pain in 53 (18%), dyspnea in 64 (21%), anosmia in 24 (8%), and ageusia in 21 (7%) patients.

HADS and HRQL at M6

HADS and SF-12 Health survey were completed in 225/324 (69%) patients at M6. Median HADS-Anxiety score was 4.0 [3.0; 7.0]; 24 (11%) patients had a HADS-Anxiety score above or equal to 11. Median HADS-Depression score was 2.0 [1.0; 5.0]; 18 (8%) patients had a HADS-Depression above or equal to 11.

Median Physical HRQL score was 50.2 [42.2 – 53.9]; 79 (35%, 95% CI [29 - 42%]) of the patients had physical HRQL lower than the 25th percentile of the distribution of the score in the general French population ($p=0.0005$); 66% of patients with a 7-symptoms score ≥ 3 at M6 has also an impaired physical HRQL.

Median mental HRQL was 51.2 [42.3 – 55.8]; 59 (26%, 95% CI [21 - 32%]) of patients had a mental HRQL lower than the 25th percentile of the distribution of the score in the general French population, which was not statistically different ($p=0.7$).

Global burden of the disease at Month 6

The combinations of 7-symptoms score ≥ 3 , anxiety, depression, and impaired physical and mental HRQL at M6 are presented in Figure S2; 116/225 (52%) patients presented at least one modality among total 7-symptoms score ≥ 3 , HADS-Anxiety score ≥ 11 , HADS-Depression score ≥ 11 , impaired physical HRQL and impaired mental HRQL. Most frequent modality and combinations were impaired physical HRQL, total 7-symptoms score ≥ 3 , and combination of impaired physical HRQL with total 7-symptoms score ≥ 3 . Twenty-eight of the 135 (21%) patients who had professional activities before admission had not returned to work at M6.

M6 evaluation as compared to previous evaluations

The proportions of patients who self-reported symptoms regardless of their severity at D1, discharge, 2 to 4 weeks after discharge, M3 and M6 are shown in Figure 2a. Self-reporting of each symptom was not significantly different between M3 and M6. Similar results were obtained in a sensitivity analysis excluding patients who were admitted to ICU at any time during hospitalization (Figure S3). Reporting of each symptom according to its severity at M3 and M6 are represented Figure 1.

Evolution of 7-symptoms total score over time is shown in Figure 2b. Of note, median 7-symptoms score in patients with at least one symptom at M6 was 9 [5 – 11], 3 [1 -6], 2 [1 – 5], 2 [1 – 3], 2 [1 – 4] at D1, discharge, 2 to 4 weeks after discharge, M3 and M6, respectively (Figure S4).

Proportion of patients with a total 7-symptoms score ≥ 3 was not significantly different between M3 (24% [19-29%]) and M6 (23% [18-28%]) ($p=0.8$). Rates of practitioner-reported symptoms, anxiety, depression and physical and mental HRQL remained also stable between M3 and M6 (Table 2).

Discussion

To our knowledge, this is the first study assessing the severity of persistent symptoms 6 months after hospital admission for COVID-19 and their evolution since admission. In our population, 56% of patients still reported at least one symptom at M6, but less than 7% rated any symptom as severe. Except for female gender, we did not identify any other factor linked to high burden of symptoms at M6 that could prompt specific follow-up management options, and thus improve patients' outcome.

The French COVID cohort was launched at the very beginning of COVID-19 pandemic when the first cases were identified in France and recruited patients in all types of French hospitals, throughout France including overseas territories. The database extraction date of March 22, 2021 made it possible to assess the health status of patients included between January 24, 2020 and September 22, 2020. The younger age of the population who responded to the questionnaire compared to those who did not, was probably explained by a greater propensity of younger people to complete a questionnaire on the WEB. The lower age of the respondents was logically associated with a lower proportion of comorbidity and of ICU admission.

The proportion of patients (approximately one out of two) who reported at least one symptom at M6 using the 7-symptom influenza questionnaire was high, with most common reported symptoms being fatigue and myalgia; this is consistent with previous studies on mid-term follow up of SARS-CoV-2 (Carfi et al., 2020; Garrigues et al., 2020; Huang et al., 2021; Xiong et al., 2021) or long term follow-up of other SARS survivors (Lam et al., 2009; Lee et al., 2007; Tansey et al., 2007), although the range of values was wide. This large range of reported symptoms could be due to differences in the characteristics of patients included in the cohort or filling the forms, such as the age, the proportions of women or of patients with comorbidities (Huang et al., 2021).

Since we did not know patients' symptoms before they experienced COVID, we were not able to assess to what extent, the M6 reported symptoms were related to the COVID episode or to a pre-existing condition. For this reason, and taking into account the experience of self-questionnaire performed in influenza, we assessed the severity of the symptoms and defined symptom alleviation as seven symptoms were scored absent or only mild (Duval et al., 2010; Hayden et al., 1997). This led to a fifth of the patients being considered to have a poor M6 clinical outcome. Beyond the proportion attributable to the COVID that cannot be precisely estimated, on one hand, the association between a score higher than three and a poor physical

quality of life, and on the other hand, the significantly higher proportion of subjects with an impaired physical quality of life compared to a control population argue for the COVID's responsibility for the symptoms reported by patients. This is all the more to be taken into account as the persistence of symptoms as well as the alteration in quality of life at M3 and M6 did not suggest a rapid improvement and invites to extend the patient follow-up beyond M6. Considering the persistence of altered quality of life between M3 and M6, especially regarding mental health, supportive cares should be taken as early as 3 months after hospitalization in patients who need it.

Female gender was found to be the sole risk factor of persistence of moderate or severe symptom, consistently with previous studies in SARS-CoV-2 survivors (Ghosn et al., 2021; Huang et al., 2021; Xiong et al., 2021), whereas women are prone to develop less severe acute COVID than men (Richardson et al., 2020; Yazdanpanah and French COVID cohort investigators and study group, 2021; Zhou et al., 2020). The pathophysiology mechanisms underlying this finding remain to be explored. Neither ICU admission, nor reporting of moderate or severe symptoms at admission which could be considered as a proxy of the disease severity at admission, were associated with poor clinical outcome at M6.

This study has several limitations. First, M3 and M6 self-administered questionnaires were not completed by all survivors. On one hand, as the population was younger and therefore less prone to have been admitted to ICU during hospitalization, our study might underestimate the proportion of COVID-19 survivors with poor clinical outcome at M6 post-hospitalization (Huang et al., 2021). On the other hand, one cannot ruled out that the propensity to complete a questionnaire is higher among those with symptoms than those without. Second, M6 assessment took place between end of July, 2020 and March, 2021, a semester during which the health situation in France deteriorated with an alternation of curfews and lockdown measures, thus promoting an anxiety-provoking climate. Differences in the patients' characteristics of those

evaluated and those not, specific health care facilities bottleneck at the time of follow-up, improvement of support of care strategies over the outbreak and evolution of virus characteristics did not allow us to impede extrapolation of our results to all survivors of COVID-19. Third, the 7-symptoms questionnaire was previously used to assess symptom alleviation in acute phase of influenza disease, but not long-term sequelae. However, when focusing on patients with a total score above or equal to 3 at M6, the same number of patients had a poor outcome and the determinants remained the same.

Identifying patients needing specific care after COVID-19 could be beneficial in terms of public health. The use of a simple web-based questionnaire with a scale of severity could be helpful to identify patients requiring appropriate medical care including psychological support within months following recovery, especially since close follow-up of all COVID-19 survivors after hospital discharge seems difficult to achieve in the context of successive epidemic waves and congestion in health-care facilities.

In conclusion, persistence of symptoms in more than half of the patients and impaired physical health-related quality of life at M6 promotes long-term follow-up beyond six months following recovery.

294 **Acknowledgment**

295 **Sources of funding:** This work was supported by the REACTing (REsearch & ACtion
296 emergING infectious diseases) consortium and by a grant of the French Ministry of Health
297 (PHRC n°20-0424).

298 **Group Information:** The members of the French COVID cohort study and investigators
299 groups are provided in Supplementary Material.

300 **Additional Information:** The study included a scientific advisory board composed of Dominique
301 COSTAGLIOLA, Astrid VABRET, Hervé RAOUL and Laurence WEISS.

302

303 **Ethics and regulatory issues**

304 The study was conducted with the understanding and the consent of each participant or its
305 surrogate. The French Ethics Committee (CPP-Ile-de-France VI, ID RCB: 2020-A00256-33)
306 has approved the study protocol.

307

References

- Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 2020;324:603. <https://doi.org/10.1001/jama.2020.12603>.
- Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, François C, et al. Health-Related Quality of Life After 1 Year of Highly Active Antiretroviral Therapy: *JAIDS J Acquir Immune Defic Syndr* 2003;32:38–47. <https://doi.org/10.1097/00126334-200301010-00006>.
- Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020;369:m1985. <https://doi.org/10.1136/bmj.m1985>.
- Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. *PLoS Med* 2010;7:e1000362. <https://doi.org/10.1371/journal.pmed.1000362>.
- Gandek B, Ware JE, Aaronson NK, Alonso J, Apolone G, Bjorner J, et al. Tests of Data Quality, Scaling Assumptions, and Reliability of the SF-36 in Eleven Countries. *J Clin Epidemiol* 1998;51:1149–58. [https://doi.org/10.1016/S0895-4356\(98\)00106-1](https://doi.org/10.1016/S0895-4356(98)00106-1).
- Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect* 2020;81:e4–6. <https://doi.org/10.1016/j.jinf.2020.08.029>.
- Ghosn J, Piroth L, Epaulard O, Le Turnier P, Mentré F, Bachelet D, et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2021;27:1041.e1-1041.e4. <https://doi.org/10.1016/j.cmi.2021.03.012>.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377–81. <https://doi.org/10.1016/j.jbi.2008.08.010>.
- Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections. *N Engl J Med* 1997;337:874–80. <https://doi.org/10.1056/NEJM199709253371302>.

350 Huang C, Huang L, Wang Yeming, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-
351 19 in patients discharged from hospital: a cohort study. *Lancet Lond Engl* 2021;397:220–32.
352 [https://doi.org/10.1016/S0140-6736\(20\)32656-8](https://doi.org/10.1016/S0140-6736(20)32656-8).
353

354 Lam MH-B, Wing Y-K, Yu MW-M, Leung C-M, Ma RCW, Kong APS, et al. Mental
355 morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term
356 follow-up. *Arch Intern Med* 2009;169:2142–7.
357 <https://doi.org/10.1001/archinternmed.2009.384>.
358

359 Lee AM, Wong JGWS, McAlonan GM, Cheung V, Cheung C, Sham PC, et al. Stress and
360 psychological distress among SARS survivors 1 year after the outbreak. *Can J Psychiatry Rev*
361 *Can Psychiatr* 2007;52:233–40. <https://doi.org/10.1177/070674370705200405>.
362

363 Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
364 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized
365 With COVID-19 in the New York City Area. *JAMA* 2020;323:2052.
366 <https://doi.org/10.1001/jama.2020.6775>.
367

368 Tansey CM, Louie M, Loeb M, Gold WL, Muller MP, de Jager J, et al. One-year outcomes and
369 health care utilization in survivors of severe acute respiratory syndrome. *Arch Intern Med*
370 2007;167:1312–20. <https://doi.org/10.1001/archinte.167.12.1312>.
371

372 Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in
373 Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect* 2021;27:89–95.
374 <https://doi.org/10.1016/j.cmi.2020.09.023>.
375

376 Yazdanpanah Y, French COVID cohort investigators and study group. Impact on disease
377 mortality of clinical, biological, and virological characteristics at hospital admission and
378 overtime in COVID-19 patients. *J Med Virol* 2021;93:2149–59.
379 <https://doi.org/10.1002/jmv.26601>.
380

381 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
382 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*
383 2020;395:1054–62. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
384

385 Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*
386 1983;67:361–70. <https://doi.org/10.1111/j.1600-0447.1983.tb09716.x>.

Figure legends

Figure 1: Frequency and severity of self-reported symptoms in patients from the French COVID cohort at 3 and 6 months (M3 and M6) after hospital admission.

Figure 2: Evolution of 7-symptoms over time in patients from the French COVID cohort.

Table 1: Baseline characteristics in patients of the French COVID cohort who fully completed the 7-symptoms questionnaire 6 months after diagnostic confirmation.

Table 2: Practitioner-reported symptoms, Hospital Anxiety and Depression scale (HADS), and Health-related quality of life (HRQL) at 3 and 6 months (M3 and M6) after hospital admission.




Figure 1: Frequency and severity of self-reported symptoms in patients from the French COVID cohort at 3 and 6 months (M3 and M6) after hospital admission.

Barplot representing each symptom severity for the N = 324 patients who fully completed their 7-symptoms questionnaire at 3 and 6 months after diagnostic confirmation. The score for each symptom is given on a four-degree scale going from 0 to 3 (i.e. none, mild, moderate, severe). The corresponding percentages are given in each colored bar. Of note, patients presenting no symptom at all are not represented on this graph.

Figure 2a.




Figure 2b.




Figure 2: Evolution of 7-symptoms over time in patients from the French COVID cohort.

a. Heatmap of the 7 self-reported symptoms. For a given symptom at a given time-point, the box is colored according to the proportion of patients reporting this symptom, and the percentage is displayed in each box. P-values of McNemar test for paired samples comparing proportions of patients reporting symptoms at 3 and 6 months (M3 and M6) after hospital admission are: Fatigue, $p=0.5$; Myalgia, $p=0.2$; Headache, $p=0.06$; Cough, $p=0.8$; Nasal obstruction, $p=1$; Sore throat, $p=0.3$; Feverishness, $p=0.2$. **b.** Boxplots of the total score obtained by adding the scores obtained for each of the 7 self-reported symptoms. The score for each symptom is given on a four-degree scale going from 0 to 3, the total score is thus comprised between 0 and 21. The red dots represent the mean values.

Table 1: Baseline characteristics in patients of the French COVID cohort who fully completed the 7-symptoms questionnaire 6 months after diagnostic confirmation.

Category	n/ntot (%) N = 324
Male Sex	205/324 (63)
Ethnic group	
White	212/264 (80)
Black	25/264 (10)
Arab	19/264 (7)
Asian	4/264 (2)
Other	4/264 (2)
Age	
Adult (18-64)	200/324 (62)
Elders (>64)	124/324 (38)
Smoking history	
Current smoker	19/265 (7)
Never smoked	171/265 (64)
Former smoker	75/265 (28)
Health worker	31/306 (10)
Intensive care unit	
At any time	54/286 (19)
At admission	33/302 (11)
Comorbidities	
Diabetes	48/311 (15)
Hypertension	110/311 (35)
Obesity	53/304 (17)
Chronic cardiac disease	57/311 (18)
Chronic pulmonary disease	56/311 (18)
Chronic kidney disease	16/311 (5)
Moderate or severe chronic liver disease	3/311 (1)
Mild chronic liver disease	4/311 (1)
Chronic neurological disorder	20/311 (6)
Malignant neoplasm	20/310 (6)
Chronic haematologic disease	16/311 (5)
AIDS/HIV	1/311 (0.3)
Dementia	1/311 (0.3)
Rheumatologic disorder	16/311 (5)

Category	n/ntot (%) N = 324
Number of comorbidities*	
0	99/311 (32)
1	94/311 (30)
2 or more	118/311 (38)

* Comorbidities were defined using the Charlson comorbidity index, with the addition of clinician-defined obesity.

Table 2: Practitioner-reported symptoms, Hospital Anxiety and Depression scale (HADS), and Health-related quality of life (HRQL) at 3 and 6 months (M3 and M6) after hospital admission.

	M3	M6
Practitioner-reported symptoms N=301		
Joint pain	51 (17%)	53 (18%)
Dyspnea	73 (24%)	64 (21%)
Anosmia	24 (8%)	24 (8%)
Ageusia	25 (8%)	21 (7%)
At least 1 among above symptom	122 (41%)	111 (37%)
HADS N= 225		
HADS-A ≥ 11	26 (12%)	24 (11%)
HADS-D ≥ 11	18 (8%)	18 (8%)
SF-12 N=225		
Impaired physical HRQL	95 (42%)	79 (35%)
Impaired mental HRQL	62 (28%)	59 (26%)

Note: HADS is divided into an anxiety (HADS-A) and depression (HADS-D) subscale. Each HADS item was scored on a 4-point Likert scale (0–3) with higher scores indicating more severe anxiety/depression. The items scores were summed up separately for HADS-A and HADS-D, leading to two scores ranging between 0 and 21. Scores between 11–21 points indicated abnormal levels. SF-12: an individual was defined as having an impaired physical (or mental) health-related quality of life if his Physical Component Summary (or Mental Component Summary) was lower than the 25th percentile of the distribution of the score in the general French population of the same age group and gender.